Purchasers of Toprol XL Would Receive $11 Million Under Proposed Settlement

A proposed settlement has been reached in a class action lawsuit alleging that AstraZeneca violated federal antitrust laws by engaging in an unlawful scheme to delay or block the market entry of less expensive, generic versions of its extended-release heart drug Toprol XL (metroprolol succinate), several law firms announced Nov. 8 (In re Metroprolol Succinate End-Payor Antitrust Litigation).

The firms that are co-lead counsel for the class said AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, and Aktiebolaget Hassle will pay up to $11 million into a settlement fund for purchasers who paid for the drug from 2005 to ...